MENU
+Compare
DNLI
Stock ticker: NASDAQ
AS OF
Sep 23, 04:59 PM (EDT)
Price
$13.05
Change
-$0.27 (-2.03%)
Capitalization
1.95B

DNLI Denali Therapeutics Forecast, Technical & Fundamental Analysis

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease... Show more

Industry: #Biotechnology
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for DNLI with price predictions
Sep 22, 2025

DNLI's RSI Indicator climbs out of oversold territory

The RSI Indicator for DNLI moved out of oversold territory on September 22, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

DNLI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 177 cases where DNLI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DNLI as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DNLI turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

DNLI moved below its 50-day moving average on September 12, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DNLI crossed bearishly below the 50-day moving average on September 17, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DNLI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.896) is normal, around the industry mean (19.858). P/E Ratio (0.000) is within average values for comparable stocks, (53.799). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.131). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. DNLI's P/S Ratio (3333.333) is very high in comparison to the industry average of (344.050).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

DNLI is expected to report earnings to rise 3.65% to -74 cents per share on October 30

Denali Therapeutics DNLI Stock Earnings Reports
Q3'25
Est.
$-0.75
Q2'25
Missed
by $0.01
Q1'25
Missed
by $0.08
Q4'24
Beat
by $0.17
Q3'24
Missed
by $0.03
The last earnings report on August 11 showed earnings per share of -72 cents, missing the estimate of -70 cents. With 1.16M shares outstanding, the current market capitalization sits at 1.95B.
A.I. Advisor
published General Information

General Information

a biotechnology company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
161 Oyster Point Boulevard
Phone
+1 650 866-8548
Employees
445
Web
https://www.denalitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMECX25.690.12
+0.47%
Victory Integrity Discovery C
CMNIX15.630.01
+0.06%
Calamos Market Neutral Income I
VGWAX34.140.02
+0.06%
Vanguard Global Wellington Admiral
ABGNX21.170.01
+0.05%
American Century Balanced R5
JERTX12.33-0.03
-0.24%
Janus Henderson Global Real Estate T

DNLI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+4.47%
NRIX - DNLI
58%
Loosely correlated
-0.12%
OCUL - DNLI
54%
Loosely correlated
+0.83%
BEAM - DNLI
54%
Loosely correlated
+0.37%
RGNX - DNLI
54%
Loosely correlated
+1.91%
IMVT - DNLI
52%
Loosely correlated
+5.48%
More